Abstract

BackgroundImaging findings for pancreatic neuroendocrine carcinoma (PNEC) and pancreatic ductal adenocarcinoma (PDAC) often overlap. The aim of this study was to demonstrate the value of computed tomography (CT) imaging features and texture analysis to differentiate PNEC from PDAC.MethodsTwenty-eight patients with pathologically-proved PDAC and 14 patients with PNEC were included in this study. CT imaging findings, including tumor boundary, size, enhancement degree, duct dilatation and parenchymal atrophy were used to compare PDAC and PNEC. CT texture features were extracted from CT images at the arterial and portal phases.ResultsMore PNEC than PDAC had well-defined margins (57.1% vs 25.0%, p = 0.04). Parenchymal atrophy was more common in PDAC than in PNEC (67.9% vs 28.1%, p = 0.02). CT attenuation values (HU) and contrast ratios of PNEC inthe arterial and portal phases were higher than those of PDAC (p < 0.05 or 0.01). Entropy was lower and uniformity was higher in PNEC compare to PDAC at the arterial phase (p < 0.05). Contrast ratio showed the highest area under curve (AUC) for differentiating PNEC from PDAC (AUC = 0.98–0.99). Entropy and uniformity also showed an acceptable AUC (0.71–0.72).ConclusionsOur data indicate that CT imaging features, including tumor margin, enhanced degree and parenchymal atrophy, as well as texture parameters can aid in the differentiation of PNEC from PDAC.

Highlights

  • Imaging findings for pancreatic neuroendocrine carcinoma (PNEC) and pancreatic ductal adenocarcinoma (PDAC) often overlap

  • Parenchymal atrophy was more common in PDAC than PNEC (67.9% vs 28.1%, p = 0.02)

  • They showed that well-defined margin and lower frequencies of ductal dilatation were more common in hypovascular pancreatic neuroendocrine neoplasms (PNENs) than PDAC

Read more

Summary

Introduction

Imaging findings for pancreatic neuroendocrine carcinoma (PNEC) and pancreatic ductal adenocarcinoma (PDAC) often overlap. The aim of this study was to demonstrate the value of computed tomography (CT) imaging features and texture analysis to differentiate PNEC from PDAC. Pancreatic neuroendocrine carcinoma (PNEC) is a rare tumor that accounts for 2–3% of pancreatic neuroendocrine neoplasms (PNENs) [1, 2]. Several studies reported that PNEC usually showed hypovascular pattern in contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) [3,4,5,6]. The treatment strategies and prognosis of PNEC and PDACs are substantially different. Several reports indicate that therapy with sunitinib or everolimus is helpful for PNEC [10, 11].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call